Charles Loftin

Contact Information

347 Bio Pharm Complex
789 South Limestone Street
Lexington, KY 40536-0596

Phone: 859-323-9892

Fax: 859-257-7564

Contact by email


  • Associate Professor
    Department of Pharmaceutical Sciences

Charles Loftin, Ph.D.

Dr. Loftin received a Ph.D. in Toxicology in 1995 from the University of North Carolina at Chapel Hill and a B.S. in Pharmacy in 1989 from Auburn University. Before joining the University of Kentucky, Dr. Loftin was a Research Fellow with the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina.

Research Interests

Dr. Loftin's lab studies the functions of prostanoids, which are lipid mediators formed by most tissues and best known for producing inflammation. Prostanoids are synthesized by the cyclooxygenases that are better known as COX-1 and COX-2. The COX enzymes are targets of nonsteroidal anti-inflammatory drugs, such as aspirin and ibuprofen, and the COX-2-selective inhibitor celecoxib. By utilizing pharmacological inhibitors of the COX enzymes together with mice genetically deficient in either COX-1 or COX-2, Dr. Loftin's lab has identified a variety of different physiological and pathophysiological processes that are dependent on either COX-1 or COX-2. These include prenatal and postnatal vascular development, protection against pathogen-induced atherosclerosis, adipose tissue differentiation, vascular remodeling associated with aortic aneurysm initiation and progression, and vascular smooth muscle cell phenotypic modulation. The goal of this work is to identify targets down-stream of the COX isoforms that will lead to the development of medications with novel therapeutic benefit and which lack the adverse effects of currently available COX inhibitors.

Selected Publications/Presentations

  • Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects. Oestreich JH, Steinhubl SR, Ferraris SP, Loftin CD, Akers WS. J Thromb Thrombolysis. 2014 Feb 8.
  • β-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice. Trivedi DB, Loftin CD, Clark J, Myers P, DeGraff LM, Cheng J, Zeldin DC, Langenbach R. Circ Res. 2013 Apr 26;112(9):1219-29.
  • Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype. Mukherjee K, Gitlin JM, Loftin CD. J Cardiovasc Pharmacol. 2012 Dec;60(6):520-9.
  • Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice. Ghoshal S, Loftin CD. PLoS One. 2012;7(11):e44369.
  • Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. Ghoshal S, Trivedi DB, Graf GA, Loftin CD. J Biol Chem. 2011 Jan 7;286(1):889-98.
  • Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice. Kelso ML, Scheff SW, Pauly JR, Loftin CD. BMC Neurosci. 2009 Aug 31;10:108.
  • Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. Gitlin JM, Loftin CD. Cardiovasc Res. 2009 Feb 1;81(2):400-7.
  • Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD. Cardiovasc Res. 2007 Jan 1;73(1):227-36.
  • Attenuated cyclooxygenase-2 expression contributes to patent ductus arteriosus in preterm mice. Trivedi DB, Sugimoto Y, Loftin CD. Pediatr Res. 2006 Dec;60(6):669-74.
  • Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. King VL, Trivedi DB, Gitlin JM, Loftin CD. Arterioscler Thromb Vasc Biol. 2006 May;26(5):1137-43.
page last modified: May 29 2014     

© University of Kentucky College of Pharmacy
Official Site of the University of Kentucky College of Pharmacy